Synonyms: ACP-2566 | analogue 4 [PMID: 15837309] | Daybue® | glycyl-alpha-methyl-L-prolyl-L-glutamic acid | NNZ-2566 | NNZ2566
trofinetide is an approved drug (FDA (2023))
Compound class:
Peptide or derivative
Comment: Trofinetide (NNZ-2566), a synthetic analogue of the amino‐terminal tripeptide of insulin-like growth factor 1 (IGF-1; GPE). It was developed as a neuroprotective agent, for potential application in neurodegenerative diseases of the central nervous system, and traumatic brain injury.
The endogenous glycine-proline-glutamate tripeptide (GPE, Glypromate) is present in the brain [7], and it has been demonstrated to partially reverse core symptoms in Mecp2-deficient mice that are a model of human Rett syndrome [8]. Trofinetide has been modified to offer a longer half-life than GPE. |
Peptide Sequence | |
GXE | |
H-Gly-aMePro-Glu-OH |
HELM Notation | |
PEPTIDE1{G.[*C(=O)[C@@]1(CCCN1*)C |$_R2;;;;;;;;_R1;$|].E}$$$$ |
Download 2D Structure | |
Canonical SMILES | Download |
Isomeric SMILES | Download |
InChI standard identifier | Download |
InChI standard key | Download |
Molecular structure representations generated using Open Babel